Last reviewed 2026-04-23 · How we verify

HGP1201

HGP1201 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.

HGP1201 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes. Used for Type 2 diabetes mellitus.

At a glance

Mechanism of action

HGP1201 binds to and activates the glucagon-like peptide-1 (GLP-1) receptor on pancreatic beta cells, stimulating glucose-dependent insulin secretion. The drug also slows gastric emptying and promotes satiety, contributing to weight loss and improved metabolic control in patients with type 2 diabetes.

Approved indications

• Type 2 diabetes mellitus

Common side effects

• Nausea
• Vomiting
• Diarrhea
• Gastrointestinal disorders

Key clinical trials

• Investigating the Pharmacokinetic Drug Interactions Between HGP1201 and HGP0904 (PHASE1)
• A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HCP1303 Capsules (PHASE3)
• PK and Safety of HCP1303 and Co-administration of HGP1201, HIP1402 Under Fed Condition in Healthy Male Volunteers (PHASE1)
• Pharmacokinetics and Safety of HCP1303 and Co-administration of HGP1201, HIP1402 in Healthy Male Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• HGP1201 CI brief — competitive landscape report
• HGP1201 updates RSS · CI watch RSS
• Hanmi Pharmaceutical Company Limited portfolio CI